BioCentury | Jan 30, 2020
Distillery Therapeutics

HDAC3 identified as obesity target

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Intestinal HDAC3 inhibition could treat obesity. In mice fed a normal diet, intestinal knockout of HDAC3 increased intestinal expression of lipid metabolism genes. In a mouse model of obesity induced...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

Entinostat-derived LSD1 and HDAC dual inhibitor for pediatric glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An HDAC and LSD1 inhibitor could treat diffuse intrinsic pontine glioma, a subtype of pediatric brain cancer. A dual HDAC and LSD1 inhibitor tool compound, derived from the HDAC...
BC Innovations | Nov 14, 2019
Targets & Mechanisms

New roles for HDACs in the cytoplasm and muscle disorders

While HDACs are known for their epigenetic function, NIBR researchers have discovered cytoplasmic HDAC4 substrates involved in muscle physiology. The findings suggest blocking HDAC4 deacetylation activity could treat muscle atrophy and other musculoskeletal disorders. HDACs...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BC Innovations | Jan 30, 2019
Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
BC Innovations | Nov 13, 2018
Distillery Therapeutics


INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting HDAC3 could help treat AD. In a HEK cell line expressing mutant APP, a tool compound HDAC3 inhibitor decreased levels of neurotoxic β amyloid...
BC Innovations | Aug 8, 2018
Distillery Therapeutics


INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of analogs...
BC Innovations | Feb 13, 2018
Distillery Therapeutics


INDICATION: Neuropathy Mouse studies suggest inhibiting HDAC3 could help treat peripheral neuropathies. In a mouse model of sciatic nerve injury, tool compound HDAC3 inhibitors increased the number of myelin-producing Schwann cells at the injury site...
BC Extra | Feb 12, 2018
Preclinical News

HDAC3 inhibition promotes peripheral remyelination

A study published in Nature Medicine identified histone deacetylase 3 (HDAC3) as a target for boosting remyelination in peripheral neuropathies. Following demyelination in a mouse model of sciatic nerve injury, researchers from Cincinnati Children’s Hospital...
BC Innovations | Jun 27, 2017
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method of Cas9 -guided histone deacetylation could be used as gene therapy to promote or repress the expression of target genes. The method involves transfecting cells with two lentiviral vectors: one...
Items per page:
1 - 10 of 32